Santa Clara, CA and Woburn, MA (OBBeC) - Agilent Technologies and BioTrove have unveiled the signing of a non-exclusive reseller agreement to enable BioTrove to provide an end-to-end solution for mass spectrometry-based drug discovery.
According to the announcement, this solution will combine BioTrove’s RapidFire Mass Spectrometry sample preparation system with Agilent’s rugged, accurate mass spectrometers. The reseller agreement expands on an established strategic relationship between Agilent and BioTrove.
BioTrove will provide an integrated solution for drug discovery using mass spectrometry analysis, affording customers access to a single system. BioTrove’s RapidFire system – comprised of robotics and microfluidic handling for sample preparation and advanced software – combined with Agilent’s Triple Quadrupole and Time-of-Flight mass spectrometry instruments create a high-throughput advanced workflow solution.
The agreement includes Agilent atmospheric pressure ionization sources with the mass spectrometers, which generate reliable quantitative and qualitative results via highly sensitive and selective mass analysis, based on the molecular composition of the target compounds.
“Our expanded collaboration enables our biopharmaceutical customers to unleash their research creativity while we focus on enhanced screening applications,” said Dr Al Luderer, president and CEO, BioTrove. “As part of this complete solution, BioTrove will offer the RapidFire system and the mass spectrometer as well as provide support for the integrated system. The seamless end-to-end solution is now available globally via collaboration between Agilent and BioTrove.”
BioTrove will offer complete systems comprised of its RapidFire system combined with a broad offering of Agilent LC/MS systems including but not limited to: Agilent’s 6410 Triple Quadrupole LC/MS system, its new 6460 Triple Quadrupole LC/MS system with Agilent Jet Stream technology and sensitivity, or its 6220 Accurate Mass Time-of-Flight LC/MS system.